Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound 34
- Development stage
- Preclinical
- Lead developer
- Escape Bio
- Modality
- Small Molecules
- Administration
- Oral, Intraperitoneal, Subcutaneous, Daily Feed
01
Overview
"Compound 34" is a generic identifier used across numerous independent research studies to refer to a wide array of distinct chemical entities. These compounds exhibit diverse mechanisms of action and are being investigated for a broad spectrum of potential applications, including various forms of cancer, osteoporosis, Parkinson's disease, spinal cord injury, malaria, fungal infections, bacterial infections, coccidiosis, and pain. Some instances of "Compound 34" are also explored for agricultural uses such as acaricides and herbicides.
02
Targets
NSD2 (Histone-lysine N-methyltransferase NSD2)HTR1F (Serotonin 5-HT1F receptor)ATR (ATR serine/threonine kinase)ADRB2 (β2)CD14 (Monocyte differentiation antigen CD14)CDK4 (Cyclin-dependent kinase 4)CNR1 (Cannabinoid receptor 1)HP (Hephaestin)CCND1 (Cyclin D1)ESR1 (ERα)MAP4K1 (Hematopoietic progenitor kinase 1)IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)LRRK2 (Leucine-rich repeat serine/threonine-protein kinase 2)PPARG (Peroxisome proliferator-activated receptor gamma)PIK3CA (Phosphoinositide 3-kinase alpha)PPOX (Protoporphyrinogen oxidase)SDH (Mitochondrial electron transport chain complex II)WEE1 (WEE1 G2 checkpoint kinase)
Beyond the preview
Go deeper on Compound 34.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Compound 34.